drug · antibody
glofitamab
Marketedupdated 6mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and diffuse large b-cell lymphoma and 6 investigational indications.
indications
investigational
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(3)
Trials studying glofitamab
- —An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- phase2Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
- phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- phase2A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- phase2A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- phase2MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
- phase3A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
News(7)
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 28d ago
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 1mo ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecificsGenentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.biospace · 1mo ago
- Roche bets up to $1B to advance next-gen bispecifics with DualitasThe partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.biospace · 2mo ago
- Roche, Dualitas team up to find bispecific drugs for immune diseasesThrough a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.biopharma_dive · 2mo ago
- Roche signs $1B deal with Dualitas to pair up on big bispecific screening driveRoche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.fiercebiotech · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that